Bispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly engage a target on the surface of cancer cell and CD3 on the surface of T-cells. TCEs promote T cell activation and lysis of tumor cells. Most TCEs in development for multiple myeloma (MM) target the B cell maturation antigen (BCMA) and differ among themselves in structure, pharmacokinetics, route and schedule of administration. CD3/BCMA TCEs produce response in ~60% of patients treated in phase 1 trials. TCEs are also in development targeting the G protein-coupled receptor, class C group 5 member D (GPRC5D) and the Fc receptor homologue 5 (FcRH5). Main toxicities are cytokine release syndrome and cytopenias. Here we review the current development and future directions of TCEs in MM.

中文翻译：

---

用于治疗多发性骨髓瘤的双特异性 T 细胞接合器

双特异性 T 细胞接合器 (TCE) 源自单克隆抗体，并同时接合癌细胞表面的靶标和 T 细胞表面的 CD3。TCE 促进 T 细胞活化和肿瘤细胞裂解。大多数针对多发性骨髓瘤 (MM) 开发的 TCE 以 B 细胞成熟抗原 (BCMA) 为靶点，它们在结构、药代动力学、给药途径和给药时间表方面各不相同。CD3/BCMA TCE 在 1 期试验中约 60% 的患者中产生反应。TCE 也在开发中，靶向 G 蛋白偶联受体、C 类第 5 组成员 D (GPRC5D) 和 Fc 受体同系物 5 (FcRH5)。主要毒性是细胞因子释放综合征和血细胞减少。在这里，我们回顾了传统文化表现形式在 MM 中的当前发展和未来方向。